Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role

Molecular Pharmacology

Volumn 66, Issue 6, 2004, Pages 1478-1490

  Small, George W ^a   Shi, Yue Y ^a   Edmund, Natalie A ^a   Somasundaram, Sivagurunathan ^a,c   Moore, Dominic T ^a   Orlowski, Robert Z ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HOUSTON VICTORIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTHRACYCLINE; BORTEZOMIB; DELTAMETHRIN; DOXORUBICIN; EPIRUBICIN; NODULARIN; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST; GENE EXPRESSION; GENE INDUCTION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MKP 1 GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; XENOGRAFT;

ANIMALS; APOPTOSIS; BORONIC ACIDS; BREAST; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; FIBROBLASTS; GENES, MYC; HUMANS; IMMEDIATE-EARLY PROTEINS; MICE; MICE, KNOCKOUT; MICE, NUDE; PHOSPHOPROTEIN PHOSPHATASE; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN-TYROSINE-PHOSPHATASE; PYRAZINES; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 9444249941     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.003400     Document Type: Article

References (39)

1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, and Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective anti-tumor agents. Cancer Res 59:2615-2622.
2. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, and Greenberg ME (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription- dependent and -independent mechanisms. Science (Wash DC) 283:1358-1362.
3. Camps M, Nichols A, and Arkinstall S (2000) Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 14:6-16,
4. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, et al. (2003a) HSP-27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 102:3379-3386.
5. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, and Anderson KC (2003b) Blockade of HSP-27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63:6174-6177.
6. Ciechanover A, Orian A, and Schwartz AL (2000) Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22:442-451.
7. Franklin CC and Kraft AS (1997) Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem 272:16917-16923.
8. Franklin CC, Srikanth S, and Kraft AS (1998) Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci USA 95:3014-3019.
9. Guo YL, Rang B, and Williamson JR (1998) Inhibition of the expression of mitogen-activated protein phosphatase-1 potentiates apoptosis induced by tumor necrosis factor-α in rat mesangial cells. J Biol Chem 273:10362-10366.
10. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, and Jordan CT (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99:16220-16225.
11. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, et al. (2003) Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534.
12. Kelly K and Chu Y (2000) The regulation of MAP kinase pathways by MAP kinase phosphataaes, in Signaling Networks and Cell Cycle Control (Gutkind JS ed) pp 165-82, Humana Press, Totowa, NJ.
13. Li J, Gorospe M, Hutter D, Barnes J, Keyse SM, and Liu Y (2001) Transcriptional induction of MKP-1 in response to stress is associated with histone H3 phosphorylation-acetylation. Mol Cell Biol 21:8213-8224.
14. Liu Y, Gorospe M, Yang C, and Holbrook NJ (1995) Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP-1-dependent gene activation. J Biol Chem 270:8377-8380.
15. Loda M, Capodieci P, Mishra R, Yao H, Corless C, Grigioni W, Wang Y, Magi-Galluzzi C, and Stork PJ (1996) Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 149:1553-1564.
16. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, et al. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136-1144.
17. Meriin AB, Gabai VL, Yaglom J, Shifrin VI, and Sherman MY (1998) Proteasome inhibitors activate stress kinases and induce HSP-72. Diverse effects on apoptosis. J Biol Chem 273:6373-6379.
18. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, and Neckers L (2004) Simultaneous inhibition of HSP-90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances anti-tumor activity. Mol Cancer Ther 3:551-556.
19. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, et al. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101:2377-2380.
20. Orlowski M and Wilk S (2000) Catalytic activities of the 20 S proteasome, a multi-catalytic proteinase complex. Arch Biochem Biophys 383:1-16.
21. Orlowski RZ and Dees EC (2003) The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res 5:1-7.
22. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, and Dang CV (1998) Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 38:4342-4348.
23. Orlowski RZ, Small GW, and Shi YY (2002a) Evidence that inhibition of p44/42 mitogen-activated protein kinase signaling is a factor in proteasome inhibitor-mediated apoptosis. J Biol Chem 277:27864-27871.
24. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, et al. (2002b) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427.
25. Pei XY, Dai Y, and Grant S (2003) The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 17:2036-2045.
26. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617.
27. Riggs CEJ (1997) Anti-tumor antibiotics and related compounds, in The Chemotherapy Source Book (Perry MC ed) pp 345-86, Williams & Wilkins, Baltimore.
28. Robertson JD, Datta K, Biswal SS, and Kehrer JP (1999) Heat-shock protein 70 anti-sense oligomers enhance proteasome inhibitor-induced apoptosis. Biochem J 344:477-485.
29. Robertson T, Wright FT and Dykstra RL (1988) (eds) Order Restricted Statistical Inference. Wiley and Sons, New York, NY.
30. L by the MAPK/ERK kinase. J Biol Chem 274:31108-31113.
31. Small GW, Somasundaram S, Moore DT, Shi YY, and Orlowski RZ (2003) Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their anti-apoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 307:861-869.
32. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, and Orlowski RZ (2002) Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62:3868-3875.
33. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, Bar-Sagi D, Jones SN, Flavell RA, and Davis RJ (2000) Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science (Wash DC) 288:870-874.
34. Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y, Yoshioka K, Masuyama N, and Gotoh Y (2004) JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23:1889-1899.
35. Voorhees PM, Dees EC, O'Neil B, and Orlowski RZ (2003) The proteasome as a target for cancer therapy. Clin Cancer Res 8:6316-6325.
36. Wang HY, Cheng Z, and Malbon CC (2003) Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 191:229-237.
37. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, and Conzen SD (2004) Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 64:1757-1764.
38. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, and Taguchi H (2004) Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 85:176-180.
39. Yu C, Rahmani M, Dent P, and Grant S (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor bortezomib. Exp Cell Res 295:555-566.